# Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines

> **NCT06411002** · PHASE2 · COMPLETED · sponsor: **Revance Therapeutics, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **DRUG:** DAXXIFY

## Key facts

- **NCT ID:** NCT06411002
- **Lead sponsor:** Revance Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-08
- **Primary completion:** 2024-12-12
- **Final completion:** 2025-02-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411002, "Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06411002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*